MPHOSPH6

Summary

MPHOSPH6 (M-phase phosphoprotein 6, HGNC:7214) is a protein-coding gene on chromosome 16q23.3, encoding M-phase phosphoprotein 6 (Q99547). RNA-binding protein that associates with the RNA exosome complex.

Predicted to enable RNA binding activity. Involved in maturation of 5.8S rRNA. Located in cytosol and nuclear lumen.

Source: NCBI Gene 10200 — RefSeq curated summary.

At a glance

• GWAS associations: 22
• Clinical variants (ClinVar): 41 total
• Druggable target: yes
• MANE Select transcript: NM_005792

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7214
Approved symbol	MPHOSPH6
Name	M-phase phosphoprotein 6
Location	16q23.3
Locus type	gene with protein product
Status	Approved
Aliases	MPP6
Ensembl gene	ENSG00000135698
Ensembl biotype	protein_coding
OMIM	605500
Entrez	10200

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000258169, ENST00000563100, ENST00000563504, ENST00000566748, ENST00000567729, ENST00000568016, ENST00000569021, ENST00000569599, ENST00000880962, ENST00000931758, ENST00000931759, ENST00000953188

RefSeq mRNA: 1 — MANE Select: NM_005792 NM_005792

CCDS: CCDS10937

Canonical transcript exons

ENST00000258169 — 5 exons

Exon	Start	End
ENSE00000920946	82170125	82170224
ENSE00000920948	82151424	82151514
ENSE00000920949	82149309	82149403
ENSE00001314521	82148162	82148863
ENSE00003484650	82164082	82164194

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 96.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.4191 / max 1240.9486, expressed in 1804 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158298	34.0252	1804
158299	0.3939	199

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	96.12	gold quality
secondary oocyte	CL:0000655	95.06	gold quality
middle temporal gyrus	UBERON:0002771	94.88	gold quality
gingival epithelium	UBERON:0001949	94.75	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.24	gold quality
lower esophagus mucosa	UBERON:0035834	94.24	gold quality
gingiva	UBERON:0001828	93.60	gold quality
esophagus mucosa	UBERON:0002469	93.54	gold quality
squamous epithelium	UBERON:0006914	93.35	gold quality
cervix squamous epithelium	UBERON:0006922	93.23	silver quality
esophagus squamous epithelium	UBERON:0006920	92.64	gold quality
skin of abdomen	UBERON:0001416	92.43	gold quality
minor salivary gland	UBERON:0001830	92.35	gold quality
rectum	UBERON:0001052	92.34	gold quality
mammalian vulva	UBERON:0000997	92.28	gold quality
hair follicle	UBERON:0002073	92.19	gold quality
tonsil	UBERON:0002372	92.14	gold quality
mouth mucosa	UBERON:0003729	92.11	gold quality
body of uterus	UBERON:0009853	92.10	gold quality
cingulate cortex	UBERON:0003027	92.04	gold quality
saliva-secreting gland	UBERON:0001044	92.01	gold quality
cerebellar hemisphere	UBERON:0002245	91.98	gold quality
anterior cingulate cortex	UBERON:0009835	91.95	gold quality
cerebellar cortex	UBERON:0002129	91.94	gold quality
smooth muscle tissue	UBERON:0001135	91.81	gold quality
monocyte	CL:0000576	91.76	gold quality
adrenal tissue	UBERON:0018303	91.75	gold quality
epithelium of esophagus	UBERON:0001976	91.66	gold quality
skin of leg	UBERON:0001511	91.65	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting MPHOSPH6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-145-3P	99.33	67.66	764
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-5190	99.15	67.76	1234
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-16-1-3P	98.70	69.23	1538
HSA-MIR-1265	98.36	66.46	598
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-6728-5P	97.79	66.33	891
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-216B-5P	97.16	66.76	1126
HSA-MIR-631	97.05	66.93	602
HSA-MIR-3674	97.01	68.86	1171
HSA-MIR-6777-3P	95.35	64.30	699

Literature-anchored findings (GeneRIF, showing 2)

• MPP6 was found to be associated with the exosome, a multiprotein complex involved in RNA degradation. (PMID:11719186)
• MPP6 is a nucleolus-specific exosome co-factor required for its role in the maturation of 5.8S rRNA. (PMID:16396833)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mphosph6	ENSDARG00000093007
mus_musculus	Mphosph6	ENSMUSG00000031843
rattus_norvegicus	LOC134479438	ENSRNOG00000038335
rattus_norvegicus	Mphosph6	ENSRNOG00000050087
caenorhabditis_elegans		WBGENE00017916

Protein

Protein identifiers

M-phase phosphoprotein 6 — Q99547 (reviewed: Q99547)

All UniProt accessions (5): Q99547, H3BNK8, H3BNT4, H3BSB3, H3BU96

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein that associates with the RNA exosome complex. Involved in the 3’-processing of the 7S pre-RNA to the mature 5.8S rRNA and play a role in recruiting the RNA exosome complex to pre-rRNA; this function may include C1D.

Subunit / interactions. Associates with the RNA exosome complex, mediated by EXOSC3. Interacts with ARHGAP18. Interacts with exosome cofactors EXOSC10 and MTREX.

Subcellular location. Nucleus. Nucleolus. Cytoplasm.

Post-translational modifications. Phosphorylated in M (mitotic) phase.

Similarity. Belongs to the MPP6 family.

RefSeq proteins (1): NP_005783* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019324	MPP6	Family

Pfam: PF10175

UniProt features (18 total): cross-link 5, helix 4, strand 2, modified residue 2, chain 1, short sequence motif 1, sequence conflict 1, turn 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6D6Q	ELECTRON MICROSCOPY	3.45
6D6R	ELECTRON MICROSCOPY	3.45
6H25	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99547-F1	76.57	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 110, 147, 37, 86, 127, 150, 153

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-9930044	Nuclear RNA decay
R-HSA-72312	rRNA processing
R-HSA-8868773	rRNA processing in the nucleus and cytosol
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 170 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GOBP_RIBOSOME_BIOGENESIS, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN, PUJANA_CHEK2_PCC_NETWORK, WEI_MYCN_TARGETS_WITH_E_BOX, GENTILE_UV_HIGH_DOSE_DN, GENTILE_UV_RESPONSE_CLUSTER_D5, TIEN_INTESTINE_PROBIOTICS_24HR_UP, MODULE_98, MULLIGHAN_NPM1_SIGNATURE_3_DN, GRUETZMANN_PANCREATIC_CANCER_UP, GOBP_MATURATION_OF_5_8S_RRNA, DANG_BOUND_BY_MYC

GO Biological Process (2): maturation of 5.8S rRNA (GO:0000460), rRNA processing (GO:0006364)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (7): exosome (RNase complex) (GO:0000178), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), nuclear exosome (RNase complex) (GO:0000176), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of RNA	2
rRNA processing in the nucleus and cytosol	1
rRNA processing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear lumen	3
cellular anatomical structure	3
intracellular anatomical structure	2
rRNA processing	1
RNA processing	1
rRNA metabolic process	1
ribosome biogenesis	1
nucleic acid binding	1
binding	1
exoribonuclease complex	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
cytoplasm	1
exosome (RNase complex)	1
nucleus	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1216 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MPHOSPH6	EXOSC1	Q9Y3B2	874
MPHOSPH6	EXOSC5	Q9NQT4	773
MPHOSPH6	EXOSC3	Q9NQT5	762
MPHOSPH6	EXOSC7	Q15024	758
MPHOSPH6	C1D	Q13901	743
MPHOSPH6	EXOSC6	Q5RKV6	743
MPHOSPH6	EXOSC8	Q96B26	723
MPHOSPH6	MTREX	P42285	708
MPHOSPH6	EXOSC4	Q9NPD3	692
MPHOSPH6	EXOSC10	Q01780	615
MPHOSPH6	ZNF208	O43345	590
MPHOSPH6	EXOSC2	Q13868	539
MPHOSPH6	GPATCH1	Q9BRR8	483
MPHOSPH6	RPL3L	Q92901	483
MPHOSPH6	ACYP2	P14621	480

IntAct

63 interactions, top by confidence:

A	B	Type	Score
EXOSC2	EXOSC10	psi-mi:“MI:0914”(association)	0.840
EXOSC4	EXOSC10	psi-mi:“MI:0914”(association)	0.840
MPHOSPH6	EXOSC10	psi-mi:“MI:0407”(direct interaction)	0.810
EXOSC10	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.810
EXOSC1	EXOSC10	psi-mi:“MI:0914”(association)	0.810
EXOSC3	EXOSC10	psi-mi:“MI:0914”(association)	0.790
EXOSC2	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.770
C1D	EXOSC10	psi-mi:“MI:0915”(physical association)	0.730
MTREX	MPHOSPH6	psi-mi:“MI:0407”(direct interaction)	0.690
MPHOSPH6	MTREX	psi-mi:“MI:0914”(association)	0.690
C1D	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
EXOSC3	MTREX	psi-mi:“MI:0914”(association)	0.640
EXOSC5	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
APP	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.560
EXOSC7	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
EXOSC4	MTREX	psi-mi:“MI:0914”(association)	0.530
EXOSC2	MTREX	psi-mi:“MI:0914”(association)	0.530
MPHOSPH6	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
RAC1	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.400
NUPR1	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.370
HSPB1	MPHOSPH6	psi-mi:“MI:0915”(physical association)	0.370
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
EXOSC8	PXN	psi-mi:“MI:0914”(association)	0.350

BioGRID (163): MPHOSPH6 (Two-hybrid), MPHOSPH6 (Affinity Capture-MS), MPHOSPH6 (Affinity Capture-MS), MPHOSPH6 (Affinity Capture-MS), MPHOSPH6 (Two-hybrid), EXOSC10 (Co-fractionation), EXOSC2 (Co-fractionation), EXOSC3 (Co-fractionation), EXOSC4 (Co-fractionation), EXOSC6 (Co-fractionation), MPHOSPH6 (Co-fractionation), MPHOSPH6 (Co-fractionation), MPHOSPH6 (Co-fractionation), MPHOSPH6 (Co-fractionation), MPHOSPH6 (Co-fractionation)

ESM2 similar proteins: A2AQ19, B5XE27, O00193, O43768, O88271, P60840, P60841, P68210, P68211, Q0IIX4, Q28GU6, Q3MHJ0, Q3MHL8, Q3T062, Q4ADK4, Q4ADK7, Q5M947, Q5RAD5, Q5RD18, Q5RKH3, Q5U2T8, Q5ZIF8, Q5ZIH9, Q5ZJ97, Q6DDU5, Q6DEB4, Q6GQG3, Q6NVR1, Q6PII3, Q75QI0, Q75UQ2, Q7TN31, Q7ZVC9, Q7ZXH9, Q8HXY9, Q8K039, Q8NDD1, Q90368, Q91WE2, Q92541

Diamond homologs: Q99547, Q9D1Q1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 51 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
KSRP (KHSRP) binds and destabilizes mRNA	8	141.0×	3e-14
mRNA decay by 3’ to 5’ exoribonuclease	7	138.8×	1e-12
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	7	123.4×	3e-12
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	7	123.4×	3e-12
Nuclear RNA decay	11	94.3×	1e-17
ATF4 activates genes in response to endoplasmic reticulum stress	8	90.6×	1e-12
Major pathway of rRNA processing in the nucleolus and cytosol	12	20.6×	9e-12

GO biological processes:

GO term	Partners	Fold	FDR
RNA catabolic process	9	85.4×	4e-13
RNA processing	9	41.0×	1e-10
rRNA processing	9	26.6×	3e-09
endocytosis	6	11.9×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	24
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1261 predictions. Top by Δscore:

Variant	Effect	Δscore
16:82164080:A:AC	donor_gain	1.0000
16:82164081:C:CC	donor_gain	1.0000
16:82164081:CT:C	donor_gain	1.0000
16:82164195:C:CC	acceptor_gain	1.0000
16:82149209:C:CA	donor_gain	0.9900
16:82149303:GGTTA:G	donor_loss	0.9900
16:82149304:GTTAC:G	donor_loss	0.9900
16:82149305:TTA:T	donor_loss	0.9900
16:82149306:TAC:T	donor_loss	0.9900
16:82149307:ACC:A	donor_loss	0.9900
16:82149308:C:A	donor_loss	0.9900
16:82156115:C:CT	acceptor_gain	0.9900
16:82164190:ATAAA:A	acceptor_gain	0.9900
16:82164191:TAAA:T	acceptor_gain	0.9900
16:82164192:AAA:A	acceptor_gain	0.9900
16:82164193:AAC:A	acceptor_loss	0.9900
16:82164194:AC:A	acceptor_loss	0.9900
16:82164196:T:C	acceptor_loss	0.9900
16:82148859:CATAT:C	acceptor_gain	0.9800
16:82148861:TATC:T	acceptor_loss	0.9800
16:82148863:TC:T	acceptor_loss	0.9800
16:82148864:C:CC	acceptor_gain	0.9800
16:82148864:CTGT:C	acceptor_loss	0.9800
16:82148865:T:G	acceptor_loss	0.9800
16:82149401:TTT:T	acceptor_gain	0.9800
16:82149404:C:CC	acceptor_gain	0.9800
16:82151512:CTC:C	acceptor_gain	0.9800
16:82164080:ACT:A	donor_gain	0.9800
16:82164081:CTC:C	donor_gain	0.9800
16:82164193:AA:A	acceptor_gain	0.9800

AlphaMissense

1074 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:82164192:A:C	F18L	0.999
16:82164192:A:T	F18L	0.999
16:82164194:A:G	F18L	0.999
16:82170128:C:A	M16I	0.998
16:82170128:C:G	M16I	0.998
16:82170128:C:T	M16I	0.998
16:82164189:C:A	M19I	0.997
16:82164189:C:G	M19I	0.997
16:82164189:C:T	M19I	0.997
16:82170129:A:G	M16T	0.997
16:82164190:A:G	M19T	0.996
16:82164193:A:G	F18S	0.996
16:82151457:T:A	R74S	0.995
16:82151457:T:G	R74S	0.995
16:82151448:G:C	F77L	0.993
16:82151448:G:T	F77L	0.993
16:82151450:A:G	F77L	0.993
16:82151458:C:G	R74T	0.992
16:82164193:A:C	F18C	0.992
16:82149316:C:G	A115P	0.990
16:82170125:C:A	K17N	0.987
16:82170125:C:G	K17N	0.987
16:82164116:A:G	W44R	0.986
16:82164116:A:T	W44R	0.986
16:82170147:G:A	S10F	0.985
16:82151458:C:A	R74I	0.984
16:82151439:A:C	F80L	0.983
16:82151439:A:T	F80L	0.983
16:82151441:A:G	F80L	0.983
16:82164183:C:A	R21S	0.983

dbSNP variants (sampled 300 via entrez): RS1000014971 (16:82147810 C>T), RS1000137562 (16:82171131 G>C), RS1000154408 (16:82170898 C>A,G), RS1000238830 (16:82156968 G>A), RS1000247053 (16:82167381 T>C,G), RS1000515442 (16:82151890 G>A), RS1000582812 (16:82168119 G>A,C), RS1000769292 (16:82167546 G>A,T), RS1000883144 (16:82164614 G>A), RS1001121455 (16:82156460 T>C,G), RS1001169319 (16:82155888 G>C,T), RS1001169810 (16:82164413 T>C), RS1001240691 (16:82149427 C>G), RS1001406002 (16:82156154 G>C), RS1001508474 (16:82165766 G>C)

Disease associations

OMIM: gene MIM:605500 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

22 associations (top):

Study	Trait	p-value
GCST001762_155	Obesity-related traits	1.000000e-06
GCST001762_381	Obesity-related traits	9.000000e-06
GCST001762_383	Obesity-related traits	3.000000e-06
GCST001762_460	Obesity-related traits	5.000000e-06
GCST001762_545	Obesity-related traits	4.000000e-07
GCST001762_632	Obesity-related traits	1.000000e-07
GCST001762_680	Obesity-related traits	9.000000e-07
GCST002828_28	Urate levels in obese individuals	1.000000e-06
GCST004744_25	Lung adenocarcinoma	6.000000e-06
GCST006803_36	Schizophrenia	2.000000e-08
GCST007102_11	Seasonality and depression	6.000000e-06
GCST008103_37	Bipolar disorder	9.000000e-08
GCST008366_12	Leukocyte telomere length	7.000000e-06
GCST008366_21	Leukocyte telomere length	1.000000e-11
GCST008504_7	Fasting glucose change (long-term)	4.000000e-06
GCST008595_183	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	4.000000e-11
GCST009856_10	Leukocyte telomere length	7.000000e-10
GCST010303_60	Nevus count or cutaneous melanoma	2.000000e-09
GCST012465_40	Bipolar disorder	3.000000e-09
GCST012489_139	Heel bone mineral density x serum urate levels interaction	2.000000e-08
GCST90000014_7	Parkinson’s disease motor subtype (tremor dominant vs postural instability/gait difficulty)	7.000000e-06
GCST90000025_331	Appendicular lean mass	1.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight
EFO:0004340	body mass index
EFO:0005109	energy expenditure
EFO:0004531	urate measurement
EFO:0006876	seasonality measurement
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0004632	nevus count
EFO:0009270	heel bone mineral density
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066427 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.14	Kd	7.206	nM	CHEMBL5653589
8.14	ED50	7.206	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148765: Binding affinity to human MPHOSPH6 incubated for 45 mins by Kinobead based pull down assay	kd	0.0072	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Methotrexate	decreases expression, affects response to substance	2
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
lead acetate	increases expression	1
methylparaben	decreases expression	1
sulforaphane	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
nickel sulfate	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
ICG 001	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Atrazine	decreases expression	1
Calcitriol	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Curcumin	decreases expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Silicon Dioxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651807	Binding	Binding affinity to human MPHOSPH6 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9KM	Ubigene HEK293 MPHOSPH6 KO	Transformed cell line	Female
CVCL_E0IC	Ubigene HeLa MPHOSPH6 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.